Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: Effect on the R2 subunit of ribonucleotide reductase

Clinical Cancer Research

Volumn 7, Issue 11, 2001, Pages 3574-3579

  Green, Dena A ^a   Wong, Stuart J ^a   Chitambar, Christopher R ^a   Antholine, William E ^b   Richardson, Des R ^c  

^a Division of Hematology/Oncology   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDE BENZOYLHYDRAZONE; DEFEROXAMINE; IRON CHELATE; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SENSITIVITY; ELECTRON SPIN RESONANCE; ENZYME INHIBITION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IC 50; IRON CHELATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROXYUREA; IRON CHELATING AGENTS; ISONIAZID; MUTATION; PROTEIN SUBUNITS; RIBONUCLEOTIDE REDUCTASES; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035181433     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells
2. Regulation of genes of iron metabolism by the iron-response proteins
3. Reduction of ribonucleotides
4. Role of ribonucleotide reductase in cell division
5. The tyrosyl free radical in ribonucleotide reductase
6. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits
7. Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis
8. Iron and free radical in ribonucleotide reductase. Exchange of iron and Mossbauer spectroscopy of the protein B2 subunit of the Escherichia coli enzyme
9. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
10. A ribonucleotide reductase gene is a transcriptional target of p53 and p73
11. Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia
12. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: Evidence for synergistic antiproliferative effects
13. Inhibition of leukemic HL60 cell growth by transferrin-gallium: Effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea
14. Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium
15. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor
16. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines
17. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines
18. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents
19. Tumor cell cytotoxicity of a novel metal chelator
20. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators
21. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase
22. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines
23. A novel lipophilic iron chelator induces apoptosis in cultured breast cancer cells but does not injure normal mammary epithelial cells
24. Effects of a single course of deferoxamine in neuroblastoma patients
25. Deferoxamine in children with recurrent neuroblastoma
26. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts
27. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma
28. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone
29. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation
30. Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine
31. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
32. Cellular adaptation to down-regulated iron transport into lymphoid leukaemic cells: Effects on the expression of the gene for ribonucleotide reductase
33. The p53 pathwayapoptosis
34. p53: Death star
35. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines
36. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline
37. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression
38. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines
39. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells
40. Iron chelators induce apoptosis in proliferating cells
41. Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13
42. Deferoxamine. A reversible S-phase inhibitor of human lymphocyte proliferation
43. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
44. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
45. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
46. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents IV: The mechanisms involved in inhibiting cell-cycle progression
47. Iron homeostasis: New tales from the crypt